ENRGISE预试验:降低老年人低度炎症的概念、原理与设计
ENRGISE预试验是一项多中心、双盲、安慰剂对照的随机预试验,旨在测试氯沙坦与ω-3鱼油两种干预降低老年人血浆IL-6水平的效果。目标纳入300名70岁及以上、IL-6在2.5–30 pg/mL且存在轻度活动受限的老年人,随机分为氯沙坦、ω-3、联合用药或安慰剂四组。该预试验将为后续确定性试验提供招募可行性、药物耐受性与初步数据。
要点
- 目标人群为70岁及以上、IL-6 2.5–30 pg/mL且步行速度<1 m/s的老年人。
- 干预为氯沙坦(最大100 mg/d)和/或ω-3鱼油(最大2.8 g/d),安慰剂对照。
- 主要结局包括IL-6、400米步行速度、SPPB、炎症标志物及安全性。
核心结论
- 该预试验旨在为后续更大规模随机试验提供招募产量、可行性、药物耐受性、依从性及初步数据,以帮助确定样本量。
研究设计与样本
- 多中心、双盲、安慰剂对照的随机预试验,在五个大学研究中心的300名70岁及以上老年人中开展。
- 参与者随机接受氯沙坦、ω-3鱼油、氯沙坦联合ω-3或安慰剂,并按各组资格分层随机。
主要发现
- 原文未报告试验结果,仅说明将提供招募产量、可行性、药物耐受性和依从性及初步数据。
关键数值与推荐
- 目标入组对象为70岁及以上、两次(至少间隔1周)血浆IL-6平均水平在2.5–30 pg/mL的男性与女性。
- 入组对象自我报告步行四分之一英里或爬一层楼梯有困难,且4米常速步行速度<1 m/s。
- 氯沙坦最大剂量为100 mg/d,ω-3鱼油最大剂量为2.8 g/d,采用滴定方案以达到安全有效降低IL-6的剂量。
临床怎么用
- 该预试验设计可为老年低度炎症与活动受限人群的干预研究提供招募、药物耐受性和依从性参考。
局限性
- 原文为预试验设计描述,尚未报告实际结果数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To test two interventions to reduce interleukin (IL)-6 levels, an indicator of low-grade chronic inflammation and an independent risk factor for impaired mobility and slow walking speed in older adults. DESIGN: The ENabling Reduction of low-Grade Inflammation in SEniors (ENRGISE) Pilot Study was a multicenter, double-blind, placebo-controlled randomized pilot trial of two interventions to reduce IL-6 levels. SETTING: Five university-based research centers. PARTICIPANTS: Target enrollment was 300 men and women aged 70 and older with an average plasma IL-6 level between 2.5 and 30 pg/mL measured twice at least 1 week apart. Participants had low to moderate physical function, defined as self-reported difficulty walking one-quarter of a mile or climbing a flight of stairs and usual walk speed of less than 1 m/s on a 4-m usual-pace walk. INTERVENTION: Participants were randomized to losartan, omega-3 fish oil (ω-3), combined losartan and ω-3, or placebo. Randomization was stratified depending on eligibility for each group. A titration schedule was implemented to reach a dose that was safe and effective for IL-6 reduction. Maximal doses were 100 mg/d for losartan and 2.8 g/d for ω-3. MEASUREMENTS: IL-6, walking speed over 400 m, physical function (Short Physical Performance Battery), other inflammatory markers, safety, tolerability, frailty domains, and maximal leg strength were measured. RESULTS: Results from the ENRGISE Pilot Study will provide recruitment yields, feasibility, medication tolerance and adherence, and preliminary data to help justify a sample size for a more definitive randomized trial. CONCLUSION: The ENRGISE Pilot Study will inform a larger subsequent trial that is expected to have important clinical and public health implications for the growing population of older adults with low-grade chronic inflammation and mobility limitations.
引用
- Manini TM, Anton SD, Beavers DP, et al. ENabling Reduction of Low-grade Inflammation in SEniors Pilot Study: Concept, Rationale, and Design. J Am Geriatr Soc. 2017. PMID: 28734043. doi:10.1111/jgs.14965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。